

27 October 2020

The Editor,
Clinical & Experimental Immunology

Dear Editor,

We are hereby submitting our manuscript entitled “**Targeting T-cell immunometabolism during transplantation**” by *Kazmi et. al.* for your kind perusal and consideration for its possible publication in your esteemed journal. We confirm that this review article is original, unpublished and is currently not under consideration for publication elsewhere. The authors listed in this manuscript comply with the journal authorship criterion.

Please permit us to describe our work briefly. Management of the immunosuppression required to maintain allografts, is a constant balancing act. Any method which can tilt the balance toward lower levels of immunosuppression and more toward tolerance would increase the number of patients who can benefit. In recent years, substantial development in the field of immunometabolism provide an opportunity to enhance T regulatory cells population. In this review, we mainly focus on T cells subsets metabolism. We also explain how targeting the metabolism of immune cells with metabolic inhibitors affects T cell population. We also highlight LKB1 signaling pathway that influence the stability of Tregs to rescue organ transplants from associated injuries and chronic rejection.

Furthermore, we believe that our review presented in the manuscript would be of general interest to the readers of the *Clinical & Experimental Immunology*.

Sincerely,

Dr. Shadab Kazmi (M.Sc, Ph.D.)
(Corresponding author)
Organ Transplant Research Section
Comparative Medicine Department
King Faisal Specialist Hospital and Research Centre
Riyadh, 12713, Saudi Arabia
Phone: +966-112162919 Extn: 34942
Email: skazmi@kfshrc.edu.sa